Patent intelligence · US
US 11396530
Bicyclic peptide ligands and uses thereof
Bicyclic peptide ligands and uses thereof
Patent details — US 11396530
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jul 26, 2022
- Expiration
- Jul 21, 2042
- Applicant
- BicycleTx Limited
- Claims
- 22
- CPC classes
- A61K, A61K38/00, A61K47/64
Quick answer
US 11396530 (Bicyclic peptide ligands and uses thereof) is held by BicycleTx Limited. Status: granted. Granted Jul 26, 2022. Expires Jul 21, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BicycleTx Limited
- Grant date
- Expiration
- Claims
- 22
- CPC classes
- A61K, A61K38/00, A61K47/64
More from BicycleTx Limited
Related pharmaceutical patents in our USPTO index.
-
US 12378288
Multimeric bicyclic peptide ligands
granted -
US 12377155
Bicyclic peptide ligands specific for PSMA
granted -
US 12350343
Bicyclic peptide ligands specific for MT1-MMP
granted -
US 12318454
Bicyclic peptide ligands specific for MT1-MMP
granted -
US 12150998
Bicyclic peptide ligands specific for P-selectin
granted -
US 12049520
Bicyclic peptide ligands specific for CD137
granted -
US 11970555
Bicyclic peptide ligands specific for transferrin receptor 1 (TfR1)
granted -
US 11970553
Heterotandem bicyclic peptide complex
granted
Frequently asked questions
What is US patent 11396530?
US 11396530 (Bicyclic peptide ligands and uses thereof) is held by BicycleTx Limited. Status: granted. Granted Jul 26, 2022. Expires Jul 21, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11396530?
BicycleTx Limited is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 57 pharmaceutical patents for this assignee.
When does US 11396530 expire?
Our index shows an expiration date of Jul 21, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.